Is oral semaglutide a game changer or nice-to-have for type 2 diabetes?
With oral semaglutide now available in the USA and Europe, what part is it likely to play in the treatment of people with type 2 diabetes in primary care?
Neil Skolnik, Professor of Family and Community Medicine at Sidney Kimmel Medical College in Philadelphia, Pennysylvania, USA, gives his view and outlines key considerations for the use of this new medication as part of a shared decision-making process with people who have type 2 diabetes.
Listen below or subscribe to this podcast on:
About the expert speaker